Pfizer ordered to withdraw journal ad

Share this article:
A UK government agency told Pfizer to take down an ad for Zyvox due to potentially misleading claims about the antibiotic. The ads had run in the British Medical Journal and claimed that Zyvox (linezolid) has “superior cure rates” compared to products containing the active ingredient vancomycin, according to the UK-based Medicines and Healthcare products Regulatory Agency (MHRA). Pfizer suspended all advertising containing the claim, MHRA said, although the agency advised the firm to continually review its advertising to ensure the right balance of risks and benefits is presented and to take appropriate action if new safety data becomes available. Pfizer wrote to healthcare professionals this week to inform them about new safety restrictions on the use of Zyvox.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.